Healthcare Industry News: Elekta
News Release - February 26, 2007
Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to University Clinic in Jena, GermanySTOCKHOLM, Sweden--(HSMN NewsFeed)--Elekta Neuromag® (STO:EKTA), the world-leading equipment for non-invasive registration of nerve cell activity using magnetoencephalography (MEG) technology, has been ordered by the Biomagnetic Center at Friedrich-Schiller-University in Jena, Germany.
The Biomagnetic Center at the Friedrich-Schiller-University in Jena will upgrade its facilities and replace its current MEG equipment with a new Elekta Neuromag system. With the new MEG system from Elekta installed, neurosurgeons, neurologists and psychiatrists at the university clinic will be able to non-invasively register nerve cell activity in the brain in real time, better and more accurate than before. Improvements that are further enhanced by the highly innovative MaxFilter(TM) software that filters all magnetic interferences and artifacts, both internal and external, and provides an analysis with more reliable data. MEG technology is for many reasons regarded as the most efficient method for tracking brain activity in real-time and Elekta offers the most comprehensive state-of-the-art system on the market today, Elekta Neuromag. Compared to EEG technology, MEG has unique sensitivity capabilities. MEG also offers functional mapping information and measurement of brain activity in real time with high spatial resolution, unlike Computer Tomography (CT) and Magnetic Resonance Imaging (MRI and fMRI) which only provide structural, anatomical, metabolic and indirect functional information. As an important complement to these technologies, MEG increases the ability to understand brain activity and to improve treatment of functional disorders in the brain.
With leading technology and a long-term commitment to the development of MEG technology and methodology, Elekta was the natural choice for the assignment to upgrade the MEG facilities at the Friedrich-Schiller-University Biomagnetic Center.
"Non-invasive, real-time brain mapping and monitoring is considered one of the most exciting developments in neuroscience today and the list of new applications for MEG is steadily growing and the number of new installations are increasing," said Tomas Puusepp, President and CEO of Elekta. "We are pleased to see an increasing interest around the world for Elekta Neuromag, having lead to several new orders and a strengthened pipeline. Elekta is currently the only MEG vendor on the market with the financial stability needed to be committed to the long-term development of MEG technology."
Elekta Neuromag 306 MEG channels sensor array has higher density than any other system on the market and thus covers the brain better with a better representation of brain activity than any other MEG system. With the industry's lowest noise to signal ratio, meaning that more useful information is acquired, and thus also the highest yield of information per sample.
The unique design of the sensors combined with advanced software makes it possible to gain data with unsurpassed detail even from the deepest realms of the brain. The system also has the highest available immunity to magnetic interference, either patient-related or external. Elekta Neuromag has also the lowest operational costs, with the longest liquid helium refill interval. Elekta Neuromag is technically one of the most sophisticated MEG/EEG devices available on the market today.
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.
Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.
Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.
With approx. 2000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.Elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.